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ABSTRACT
Introduction: Plaque psoriasis can significantly
impact patients’ quality of life. We assessed
psychometric properties of the Psoriasis Symp-
toms and Impacts Measure (P-SIM), developed
to capture patients’ experiences of signs, symp-
toms and impacts of psoriasis.
Methods: Pooled, blinded, 16-week data from
1002 patients in the BE VIVID and BE READY
bimekizumab phase 3 trials were analysed. The
suitability of the P-SIM missing score rule
(weekly scores considered missing if C 4 daily
scores were missing) was assessed. Test–retest
reliability was evaluated using intraclass corre-
lation coefficients (ICCs). Convergent validity
was assessed between P-SIM and relevant
patient-reported outcome (PRO) (Dermatology
Life Quality Index [DLQI], DLQI item 1 [skin
symptoms], Patient Global Assessment of Pso-
riasis) and clinician-reported outcome (ClinRO)
scores (Psoriasis Area and Severity Index [PASI],
Investigator’s Global Assessment [IGA]) at
baseline and week 16. Known-groups validity
was assessed, comparing P-SIM scores between
patient subgroups predefined using PASI/IGA
scores. Sensitivity to change over 16 weeks was
evaluated; responder definition (RD) thresholds
were explored.
Results: The missing score rule used did not
impact P-SIM scores. Test–retest reliability
analyses demonstrated excellent score repro-
ducibility (ICC 0.91–0.98). Inter-item correla-
tions at baseline and week 16 were strong
([0.5), apart from ‘‘choice of clothing’’ with
‘‘skin pain’’ and ‘‘burning’’ at baseline (both
0.49). All P-SIM scores were moderately to
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strongly correlated with other outcomes,
demonstrating convergent validity, apart from
ClinROs (PASI, IGA) at baseline that had low
variability. P-SIM scores discriminated known
groups at week 16, confirming known-groups
validity. Changes from baseline to week 16 in
P-SIM and other clinically relevant outcomes
were strongly correlated ([0.5; weaker with
ClinROs), establishing sensitivity to change.
Anchor-based RD analyses determined a four-
point P-SIM item score decrease as indicative of
marked clinically meaningful improvement.
Conclusion: P-SIM scores demonstrated good
reliability, validity and sensitivity to change. A
four-point RD threshold could be used to assess
16-week treatment effects.
Trial Registration: BE VIVID: NCT03370133;
BE READY: NCT03410992.
Keywords: Bimekizumab; Patient-reported
outcome; Plaque psoriasis; Psychometric
validation; Responder definition
Key Summary Points
Why carry out this study?
The clinical manifestations of plaque
psoriasis have been shown to severely
impact patients’ quality of life and
emotional well-being; therefore, it is
important to measure patient experience
alongside clinical parameters in the
evaluation of treatments for plaque
psoriasis.
The Psoriasis Symptoms and Impacts
Measure (P-SIM) is a novel, patient-
reported outcome tool developed to
specifically capture patients’ experiences
of the key signs, symptoms and impacts of
plaque psoriasis; here, it was completed
daily by patients at home on a handheld
device on a 0–10 numeric rating scale, and
item scores were derived as averages of
daily scores over a week.
In these analyses, the psychometric
properties of the P-SIM were evaluated
using data pooled from the first 16 weeks
of the BE VIVID and BE READY phase 3
trials investigating bimekizumab in the
treatment of moderate to severe plaque
psoriasis.
What was learned from this study?
In these analyses, the 14 item scores of the
P-SIM demonstrated good reliability,
validity and sensitivity to change in the
assessment of patients’ experiences of key
psoriasis signs, symptoms and impacts
when completed daily on a handheld
device over a period of 16 weeks.
Anchor-based analyses determined a
4-point decrease in item scores of the
P-SIM as indicative of a marked clinically
meaningful improvement when the P-SIM
was completed daily on a handheld
device; this threshold can be used to assess
treatment effects over 16 weeks in patients
with moderate to severe plaque psoriasis.
INTRODUCTION
Psoriasis is an immune-mediated, chronic,
inflammatory skin disease that can take a vari-
ety of forms [1]. The symptoms most frequently
experienced by patients with psoriasis include
itching and scaling [2], and the clinical mani-
festations of psoriasis can have wide-ranging
impacts on quality of life and emotional well-
being [3–5]; therefore, it is important to mea-
sure patient experience alongside clinical
parameters. Understanding patients’ experi-
ences of psoriasis and needs due to their disease
is key to supporting their treatment.
Patient-reported outcome measures have
been developed to assess quality of life in
patients with skin conditions. For example, the
Dermatology Life Quality Index (DLQI) is
widely used to assess quality of life changes in
dermatology. However, it is not specific to
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psoriasis, so may not fully capture the experi-
ences of patients with this disease [6, 7]. Psori-
asis-specific tools have also been developed for
use in specific clinical trials, such as the 16-item
Psoriasis Symptom Diary [8, 9], the Psoriasis
Symptoms Scale, which captures severity of
pain, redness, itching and burning [10], and the
single-item Itch Numeric Rating Scale [11],
among others [12–14]. These instruments assess
patient-reported signs and symptoms of psoria-
sis. However, they are not available for use in
the clinical evaluation of new treatments, and
some of these instruments may omit relevant
signs, symptoms and impacts.
The Psoriasis Symptoms and Impacts Mea-
sure (P-SIM) was developed to capture patients’
experiences of the signs, symptoms and impacts
of psoriasis in the bimekizumab in plaque pso-
riasis clinical programme. It was designed as a
14-item daily electronic diary that can be com-
pleted at home by the patient for ease of use.
The development and validity of the P-SIM
content have been described previously,
including a literature review investigating
commonly reported signs, symptoms and
impacts of plaque psoriasis, clinical expert
interviews and patient interviews for the pur-
poses of concept elicitation, cognitive debrief-
ing and usability testing [15]. Quantitative
analyses following these steps led to the finali-
sation of the 14 items of the P-SIM [15]. In
addition to content validity, the US Food and
Drug Administration (FDA) also recommends
assessment of other psychometric properties of
newly developed patient-reported outcome
measures (reliability, construct validity, and
ability to detect change) [16], and determina-
tion of thresholds for interpreting the clinical
meaningfulness of within-patient score changes
over a predetermined time period (a responder
definition [RD]) [16]. To date, no RD thresholds
have been reported for the P-SIM.
Here, the psychometric properties of the
P-SIM are assessed using data from the BE VIVID
(NCT03370133) and BE READY (NCT03410992)
phase 3 trials, as well as the suitability of the
weekly missing data rule that is currently
applied to the instrument. RD thresholds for the
P-SIM items are also estimated.
METHODS
Study Design
Blinded data were pooled from the first
16 weeks of the BE VIVID and BE READY
phase 3 trials investigating bimekizumab in the
treatment of moderate to severe plaque
psoriasis.
BE VIVID was a randomised, double-blinded,
placebo- and active comparator-controlled
phase 3 study (Supplementary Fig. 1a). Patients
in BE VIVID were randomised 4:2:1 to bimek-
izumab 320 mg every 4 weeks (Q4W), ustek-
inumab 45/90 mg (by weight) administered at
baseline and then every 12 weeks (Q12W) from
week 4, or placebo for initial treatment
(weeks 0–16). BE READY was a double-blinded,
placebo-controlled, randomised withdrawal
phase 3 study (Supplementary Fig. 1b). Patients
in BE READY were randomised 4:1 to bimek-
izumab 320 mg Q4W or placebo for initial
treatment (weeks 0–16). Both trials enrolled
adult patients with a diagnosis of moderate to
severe plaque psoriasis C 6 months prior to
screening, with baseline Psoriasis Area and
Severity Index (PASI) C 12 (on a scale from
0–72), C 10% body surface area (BSA) affected
and an Investigator’s Global Assessment (IGA)
score C 3 on a 5-point scale. The co-primary
endpoints for both studies were 90% improve-
ment in PASI (PASI 90) and IGA 0/1 (0 [clear] or
1 [almost clear] with C 2-category improve-
ment from baseline) responses at week 16. Full
study designs and efficacy and safety outcomes
have been reported previously [17, 18].
The study protocols, amendments and
patient informed consent were reviewed by a
national, regional or independent ethics com-
mittee or institutional review board. BE VIVID
(NCT03370133) and BE READY (NCT03410992)
were conducted in accordance with the current
version of the applicable regulatory and Inter-
national Conference on Harmonisation (ICH)-
Good Clinical Practice (GCP) requirements, the
ethical principles that have their origin in the
principles of the Declaration of Helsinki, and
the local laws of the countries involved.
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Measurements and Outcomes
The P-SIM e-diary was to be completed daily in
the evening by patients at home via a handheld
electronic device from baseline through
week 16. It consisted of 14 items, listed in
Table 1. Each item was scored for worst severity
or level of impact in the previous 24 h on a scale
from 0 to 10 (0 meaning ‘‘no sign, symptom or
impact’’, 10 meaning ‘‘very severe sign, symp-
tom or impact’’). Average weekly scores were
derived for each of the 14 P-SIM items. Weekly
scores were considered missing if C 4 daily
scores were missing for that week.
Other outcomes reported in BE VIVID and
BE READY relevant to this validation analysis
include PASI, IGA, DLQI, and Patient Global
Assessment of Psoriasis (PGAP). The DLQI con-
sists of ten items, each scored from 0 to 3, with 3
representing the highest impact (overall score
range 0–30) [7]. DLQI item 1 (Question: ‘‘over
the last week, how itchy, sore, painful, or
stinging has your skin been?’’; answer: ‘‘not at
all’’, ‘‘a little’’, ‘‘a lot’’, or ‘‘very much’’) is specific
to skin symptoms commonly seen in psoriasis
and is considered individually in these analyses.
The PGAP consists of a multiple-choice ques-
tion (‘‘How severe are your psoriasis-related
symptoms right now?’’), with answers scored
from 1 to 5 (1, ‘‘no symptoms’’; 2, ‘‘mild symp-
toms’’; 3, ‘‘moderate symptoms’’; 4, ‘‘severe
symptoms’’; 5, ‘‘very severe symptoms’’). Both
Table 1 Items of the P-SIM
Item Response scale
1. During the past 24 h, how severe was your worst skin itching? 0 (No itching)–10 (Very severe itching)
2. During the past 24 h, how severe was your worst skin redness? 0 (No skin redness)–10 (Very severe skin redness)
3. During the past 24 h, how severe was your worst skin pain? 0 (No skin pain)–10 (Very severe skin pain)
4. During the past 24 h, how severe was your worst skin burning? 0 (No skin burning)–10 (Very severe skin burning)
5. During the past 24 h, how severe was your worst skin scaling? 0 (No skin scaling)–10 (Very severe skin scaling)
6. During the past 24 h, how severe was your worst skin cracking? 0 (No skin cracking)–10 (Very severe skin cracking)
7. During the past 24 h, how severe was your worst skin dryness? 0 (No skin dryness)–10 (Very severe skin dryness)
8. During the past 24 h, how severe was your worst skin irritation? 0 (No skin irritation)–10 (Very severe skin irritation)
9. During the past 24 h, how severe was your worst skin sensitivity? 0 (No skin sensitivity)–10 (Very severe skin
sensitivity)
10. During the past 24 h, how severe was your worst skin lesions
(red marks, spots, or inflammation)?
0 (No skin lesions)–10 (Very severe skin lesions)
11. During the past 24 h, how severe was your worst skin
thickening (hardening or roughening)?
0 (No skin thickening)–10 (Very severe skin
thickening)
12. During the past 24 h, at its worst, how severe was your
psoriasis-related fatigue (weariness, tiredness)?
0 (No fatigue)–10 (Worst possible fatigue)
13. During the past 24 h, at its worst, how much embarrassment
did you feel as a result of your psoriasis?
0 (No feelings of embarrassment)–10 (Worst possible
feelings of embarrassment)
14. During the past 24 h, at its worst, how much did your psoriasis
impact your choice of clothing?
0 (No impact on my choice of clothing)–10
(Completely impacted my choice of clothing)
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the DLQI item 1 and PGAP represent verbal
rating scales. Details of PASI and IGA score
measurements can be found in the Supple-
mentary Methods [19, 20]. The PGAP was
completed on the same electronic device as the
P-SIM; all other outcome data were collected on
a tablet during on-site study visits (week 0, 1, 2,
4, 8, 12 and 16).
Confirmation of Weekly Scoring Rule
Analyses were conducted to establish whether
alternatives to the currently applied weekly
scoring rule for the P-SIM, in which weekly item
scores are considered missing for patients in
weeks where they had C 4 missing daily scores
in that item, impacted the variability of weekly
item scores.
Patients with no missing data were included
for analysis of each item. Scenarios for the
number of days missing (1, 2, 3, 4, 5 or 6 days
missing) were simulated using a bootstrapping
method with replacement by randomly sam-
pling the appropriate number of daily scores for
that missing day scenario and calculating aver-
age weekly scores. For each missing day scenario
for a given item, each patient’s simulated
weekly score was the mean of 100 replications
of a random selection of daily scores. Means and
standard deviations (SDs) were calculated for
each item for each patient for the non-missing
case and each missing day scenario. Overall
means and SDs were also calculated for each
item by pooling the weekly scores of patients.
The SDs for missing and non-missing scenarios
for each item were compared by visual inspec-
tion and the Brown–Forsythe test.
Psychometric Validation
Construct Validity
Convergent validity was assessed for P-SIM
items by calculating Spearman’s rank correla-
tion coefficients at baseline and week 16 for
inter-item correlations and correlations
between P-SIM item scores and clinician-re-
ported outcome (PASI total score and IGA score)
and patient-reported outcome (DLQI total
score, DLQI item 1 score and PGAP score)
scores. Only pairs assessed on the same date
were included in these analyses.
A correlation coefficient[0.3 and B 0.5
indicated moderate convergent validity, and
[0.5 indicated strong convergent validity [21].
It was hypothesised that P-SIM items would
have strong correlations with each other, and
moderate to strong correlations with PASI, IGA,
DLQI and PGAP total scores. Items 1, 3, 4 and 8
(itching, skin pain, burning and irritation,
respectively) of the P-SIM were expected to have
strong correlations with DLQI item 1.
The ability of P-SIM items to discriminate
between clinically different groups of patients,
predefined according to relevant clinician-re-
ported outcomes, was also assessed. Mean P-SIM
item scores were assessed at week 16 in known
subgroups of patients defined on the basis of
absolute PASI total score thresholds (B 1,[1 to
B 3,[3 to\ 5, C 5 to\12, and C 12) and IGA
scores (0, ‘‘clear’’; 1, ‘‘almost clear’’; 2, ‘‘mild’’;
3, ‘‘moderate’’; and 4, ‘‘severe’’) at week 16. PASI
and IGA are well-accepted clinical measures of
psoriasis disease severity and were used to
define the primary efficacy endpoints in the
bimekizumab phase 3 studies, BE VIVID and
BE READY. As expected, as a result of the
inclusion criteria of the BE VIVID and
BE READY trials (PASI C 12, IGA C 3), there was
low variability in scores for both measures at
baseline; assessment of known-groups validity
therefore focused on week 16. The absolute PASI
values 1, 3 and 5 used to define subgroups have
been shown to provide reliable estimates of
disease activity that can be used to define
treatment goals for psoriasis treatment and
facilitate clinical decisions [22], while an abso-
lute PASI value of 12 was used to define mod-
erate to severe plaque psoriasis in the BE VIVID
and BE READY inclusion criteria. The IGA val-
ues used to define subgroups with clinically
different psoriasis severity levels are the
response options of the 5-point IGA scale,
which has been shown to be a valid and reliable
measure of psoriasis severity [20].
It was hypothesised that P-SIM item score
means and SDs would be higher in patients with
higher PASI and IGA scores. P values from the
Kruskal–Wallis test were calculated to compare
distributions among the known groups.
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Test–Retest Reliability
Intraclass correlation coefficients (ICCs; calcu-
lated as the ratio of the between-patient vari-
ance to the total variance) were calculated for
each item’s score between baseline and week 2
in stable patients during this period. Stable pa-
tients were defined as those whose IGA score did
not change in this interval. ICCs C 0.70 were
considered acceptable for test–retest reliability
[23].
Sensitivity to Change Over Time
Spearman’s correlation coefficients and p values
were calculated between changes from baseline
to week 16 in P-SIM item scores and in other
clinically relevant outcomes (PASI, IGA, PGAP,
DLQI item 1 and DLQI). Correlations using the
change from baseline to week 12 for PGAP were
assessed as a sensitivity analysis; this was
because a large amount of PGAP data were
missing at week 16 as a result of technical lim-
itations of the electronic device. A Spearman
correlation C 0.30 was considered to demon-
strate acceptable responsiveness [24].
Determination of Responder Definition
Anchor-based analyses were performed in line
with the recommendations for defining
response thresholds for within-patient mean-
ingful changes provided in the FDA patient-re-
ported outcome guidance. Distribution-based
analyses were conducted to provide supportive
information around the variability of the scores,
as per FDA guidance [16]. Triangulation was
performed, examining the estimates from the
anchor-based analyses and considering the dis-
tribution-based analyses as supportive informa-
tion, to estimate values for clinically
meaningful changes in each P-SIM item score.
For the anchor-based analyses, only anchors
with Spearman correlation C 0.30 between
changes from baseline to week 16 in the anchor
(week 12 for PGAP) and P-SIM items were con-
sidered. The anchors used, based on PASI, IGA,
DLQI, DLQI item 1 and PGAP response, are
shown in Supplementary Table 1. As a result of
small sample sizes (n\15) in some anchor
response categories, some of the adjacent orig-
inal categories were collapsed.
Actual mean change scores from baseline to
week 16 were calculated for each level of
improvement in each anchor. The empirical
cumulative distribution function (eCDF) and
probability density function (PDF) curves of
observed changes at week 16 for each P-SIM
item were plotted separately for each responder
group for each anchor. These curves were
examined to see if separation between levels of
response on anchors could be observed. If so,
actual change scores that optimally differenti-
ated responders from non-responders were
identified to support determination of the RD
for each item. Effect sizes for each level of
change in the anchors were estimated, and 95%
confidence intervals for the observed mean
change were calculated using bootstrapping
methods.
Distribution-based analyses used the stan-
dard error of measurement for P-SIM items, and
half an SD of item scores at baseline and study
visits [25, 26]. If the SD changed significantly
over time, the baseline SD was used; otherwise
the mean was used.
Items 1 (itching), 3 (skin pain) and 5 (scal-
ing) of the P-SIM were prioritised in the RD
analyses owing to their clinical relevance,
importance to patient experience, and use as
efficacy endpoints in the BE VIVID and
BE READY trials.
RESULTS
Patient Disposition and Baseline
Characteristics
In BE VIVID, 567 patients were randomised at
baseline: 321 to bimekizumab, 163 to ustek-
inumab and 83 to placebo. In BE READY, 435
patients were randomised at baseline: 349 to
bimekizumab and 86 to placebo. Blinded
16-week data were pooled for the 1002 patients
randomised across both studies.
Demographics and baseline disease charac-
teristics are shown in Table 2. No major differ-
ences were noted between studies, except for
race/region; BE VIVID included patients from
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Age, years, mean (SD) 46.1 (13.9) 44.3 (12.9) 45.3 (13.5)
Gender, n (%)
Male 406 (71.6%) 313 (72.0%) 719 (71.8%)
Female 161 (28.4%) 122 (28.0%) 283 (28.2%)
Race, n (%)
White 420 (74.1%) 403 (92.6%) 823 (82.1%)
Black or African American 12 (2.1%) 6 (1.4%) 18 (1.8%)
Asian 127 (22.4%) 18 (4.1%) 145 (14.5%)
American Indian or Alaska native 2 (0.4%) 0 (0.0%) 2 (0.2%)
Native Hawaiian or other Pacific islander 0 (0.0%) 2 (0.5%) 2 (0.2%)
Other or mixed 6 (1.1%) 6 (1.4%) 12 (1.2%)
Country, n (%)
USA 116 (20.5%) 85 (19.5%) 201 (20.1%)
Canada 61 (10.8%) 89 (20.5%) 150 (15.0%)
Belgium 6 (1.1%) 0 (0.0%) 6 (0.6%)
Germany 62 (10.9%) 38 (8.7%) 100 (10.0%)
Italy 4 (0.7%) 0 (0.0%) 4 (0.4%)
UK 7 (1.2%) 6 (1.4%) 13 (1.3%)
Hungary 27 (4.8%) 31 (7.1%) 58 (5.8%)
Poland 143 (25.2%) 150 (34.5%) 293 (29.2%)
Russian Federation 19 (3.4%) 19 (4.4%) 38 (3.8%)
Australia 14 (2.5%) 10 (2.3%) 24 (2.4%)
Japan 108 (19.0%) 0 (0.0%) 108 (10.8%)
Korea 0 (0.0%) 7 (1.6%) 7 (0.7%)
Duration of disease, years, mean (SD) 17.1 (12.0) 19.5 (13.1) 18.1 (12.6)
Baseline PASI, n (%)
PASI\ 20 326 (57.5%) 274 (63.0%) 600 (59.9%)
PASI C 20 240 (42.3%) 161 (37.0%) 401 (40.0%)
Missing 1 (0.2%) 0 (0.0%) 1 (0.1%)
BSA affected by psoriasis, %, mean (SD) 28.2 (16.9) 24.5 (15.4) 26.6 (16.3)
mNAPSI total score, mean (SD) 12.8 (18.8) 12.3 (19.4) 12.6 (19.0)
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Japan (19.0%), while BE READY did not. The
majority of patients were white (82.1%) and
male (71.8%), and 40.0% of patients had a
baseline PASI C 20, with the mean BSA affected
by psoriasis being 26.6%.
P-SIM Completion Rates
Completion rate (number of patients with a
non-missing weekly item score divided by the
number of patients randomised at baseline) for
the P-SIM ranged from 89.0% at week 1 to
77.8% at week 16. There were no item-level
missing P-SIM data; patients either completed
all items or no items.
Confirmation of Weekly Scoring Rule
There were 821 patients (81.9%) who had at
least one week with zero daily scores missing;
these patients were included in these analyses.
For all items and for all missing day scenarios,
the SDs found through simulations were not
statistically different to those from the ‘zero
days missing’ scenario, and the mean item
scores were similar (Supplementary Table 2).
This suggests that P-SIM item score mean and
variability remain similar regardless of the
missing score rule applied, confirming that the
weekly scoring rule used here (in which weekly
scores were considered missing if C 4 daily
scores were missing for that week) is acceptable.
Psychometric Validation
Construct Validity
As hypothesised, P-SIM items demonstrated
strong inter-item convergent validity (Supple-
mentary Table 3): almost all P-SIM items were
strongly correlated (Spearman’s correlation
coefficient, r[0.5) with each other at both
baseline and week 16, with the exception of
item 14 (choice of clothing) with items 3 (skin
pain) and 4 (burning) at baseline (r = 0.49).
As expected, P-SIM items 1, 3, 4 and 8 (itch-








PGADA for arthritis VAS Score, mean (SD) 20.1 (27.5) 24.7 (27.7) 22.1 (27.6)
Nail involvement, n (%)
Yes 354 (62.4%) 260 (59.8%) 614 (61.3%)
No 213 (37.6%) 175 (40.2%) 388 (38.7%)
mNAPSI total score for patients with nail involvement
n 354 260 614
Mean (SD) 20.3 (20.2) 20.6 (21.4) 20.4 (20.7)
Scalp involvement, n (%)
Yes 530 (93.5%) 397 (91.3%) 927 (92.5%)
No 37 (6.5%) 38 (8.7%) 75 (7.5%)
Palmoplantar involvement, n (%)
Yes 227 (40.0%) 161 (37.0%) 388 (38.7%)
No 340 (60.0%) 274 (63.0%) 614 (61.3%)
BSA body surface area affected, mNAPSI modified Nail Psoriasis Severity Index, PASI Psoriasis Area and Severity Index,
PGADA Patient Global Assessment of Disease Activity, SD standard deviation, VAS visual analogue scale
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respectively) were strongly correlated with
DLQI item 1 score at both time points (Supple-
mentary Table 4). All P-SIM items were moder-
ately to strongly correlated with DLQI total
score, DLQI item 1 score and PGAP score at both
baseline and week 16 (week 12 scores were used
for PGAP because of substantial amounts of
missing data at week 16). Lower correlations
were observed between P-SIM outcomes and the
clinician-reported outcomes, PASI total score
and IGA score, at baseline. This can be
explained by the low variability in PASI total
score and IGA at baseline, and was expected
owing to the inclusion criteria of both studies
(PASI C 12 and IGA C 3). Strong correlations
with clinician-reported outcomes were, how-
ever, observed at week 16 across nearly all items
(with the exception of items 12 [fatigue] and 14
[choice of clothing], for which correlations were
moderate, ranging from 0.46 to 0.50 at
week 16).
The P-SIM behaved as expected across all
items when discriminating between known
groups of patients defined on the basis of clin-
ically relevant outcomes, with higher P-SIM
item scores seen in patient known groups with
higher PASI total score and IGA score (Fig. 1 and
Supplementary Fig. 2) at week 16.
Sensitivity to Change Over Time
Changes from baseline to week 16 in all P-SIM
item scores had strong Spearman correlation
coefficients (r[ 0.50) with those in the other
patient-reported outcomes (DLQI total score,
DLQI item 1 and PGAP [change from baseline to
week 12 was used for PGAP as a result of sub-
stantial missing data at week 16]), with the
exception of P-SIM item 14 with DLQI item 1
(r = 0.50) (Table 3). Moderate correlations were
seen between changes from baseline to week 16
in P-SIM item scores and the clinician-reported
outcomes, PASI and IGA (r C 0.38 for all items).
Generally, changes from baseline in P-SIM
items 12, 13 and 14 (fatigue, embarrassment
and choice of clothing) had lower correlations
with those in other outcome scores; however,
changes from baseline in DLQI total score had
the highest correlations with changes from
baseline in P-SIM items 13 and 14).
Test–Retest Reliability
ICCs for all P-SIM items were well above the
acceptability threshold of 0.70, ranging from
0.91 (item 5—scaling) to 0.98 (item 12—fatigue,
item 13—embarrassment and item 14—choice
of clothing) (Table 4). This indicates excellent
test–retest reliability of P-SIM items.
Determination of Responder Definition
Supplementary Table 1 shows the response cat-
egorisations used for each anchor. The mean
P-SIM item score changes obtained for one level
of improvement in the anchors were considered
as appropriate RD thresholds. The eCDF curves
for one level of improvement consistently sep-
arated from those in the no meaningful change
groups. Collapsing of improvement categories
for the PASI percentage change from baseline,
PASI total score and IGA change from baseline
anchors, as a result of small sample sizes in
certain categories, mechanically increased the
observed mean changes from baseline to
week 16 in P-SIM item scores, making the
thresholds obtained from these anchors more
conservative.
Values obtained for one level of improve-
ment in DLQI item 1 were prioritised over other
anchors. This was because its change from
baseline to week 16 generally had the highest
correlation with those of P-SIM items, it is
patient-reported, it is measured on an ordinal
scale with directly interpretable verbal descrip-
tors, and eCDF and PDF findings supported the
thresholds obtained using it. Results obtained
using anchors based on PASI total score, IGA
change from baseline and DLQI total score were
also considered in the triangulation process,
though were deprioritised as they did not
meet all of the above criteria. IGA absolute score
and PGAP change from baseline-derived
thresholds were considered as supportive only
(IGA had only one improvement level, and
PGAP had a substantial amount of missing data
at week 16 leading to week 12 being used).
The P-SIM item RD thresholds found using
mean score changes ranged from - 2.72
(item 12—fatigue) to - 4.39 (item 5—scaling)
(Supplementary Table 5). Distribution-based
Dermatol Ther (Heidelb) (2021) 11:1551–1569 1559
values were much smaller than anchor-based
values, as expected; these were considered as
supportive only. The mean change in P-SIM
item scores obtained with one-point improve-
ment on DLQI item 1, the prioritised anchor,
were close to the four-point FDA-recommended
threshold. A four-point threshold also discrim-
inated between known groups based on other
anchors and was thus considered appropriate
for the RD across all items. Inspection of eCDF
and PDF curves supported this finding for all
items (P-SIM items 1, 3 and 5 were of primary
consideration; their CDF curves for DLQI item 1
and PASI are presented in Figs. 2 and 3). On the
basis of these results, a four-point reduction on
each P-SIM item is considered to represent a
marked clinical improvement and can be used
to define responders in patients with moderate
Fig. 1 P-SIM items 1, 3 and 5 scores at week 16 by IGA
score and PASI total score subgroups. a P-SIM item 1
(itching). b P-SIM item 3 (skin pain). c P-SIM item 5
(scaling). Data were pooled from BE VIVID and
BE READY. Black circular markers indicate mean scores
and blue circular markers indicate outliers. IGA Investi-
gator’s Global Assessment, PASI Psoriasis Area and
Severity Index, P-SIM Psoriasis Symptoms and Impacts
Measure
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to severe plaque psoriasis treated over a 16-week
period.
DISCUSSION
This study aimed to evaluate the psychometric
properties of the P-SIM to complement the
previously published evidence for its content
validity [15]. Specifically, comprehensive psy-
chometric assessment of the P-SIM item scores,
including convergent and known-groups valid-
ity, test–retest reliability and sensitivity to
change over time, was complemented by
assessment of the currently applied missing data
rule and estimation of the RD threshold for
P-SIM items, as recommended by FDA
guidelines [16]. The 14 items are not combined
into an overall summary score; while this means
that the P-SIM does not produce one number
providing an overview of all patient symptoms,
it does allow individual and specific capture of
various independent signs, symptoms and
impacts of plaque psoriasis. Other instruments
that use fewer items are simpler to analyse, but
capture fewer concepts [11, 13].
Blinded data were used for the psychometric
validation and RD analyses, removing sources
of potential bias. The applied weekly missing
score rule, in which weekly item scores were set
to ‘missing’ if C 4 daily scores were missing for
that item, was found to be adequate. The P-SIM
item scores were shown to have excellent
test–retest reliability, with all ICCs C 0.91, well
Table 3 Spearman correlations between changes from baseline to week 16 in P-SIM item scores and other clinician- and
patient-reported outcomes











Item 1—itching 0.42 0.61* 0.74* 0.48 0.72*
Item 2—redness 0.45 0.61* 0.68* 0.50 0.74*
Item 3—skin pain 0.44 0.60* 0.69* 0.46 0.68*
Item 4—burning 0.44 0.61* 0.70* 0.48 0.69*
Item 5—scaling 0.49 0.61* 0.66* 0.53* 0.73*
Item 6—cracking 0.43 0.60* 0.65* 0.47 0.68*
Item 7—dryness 0.44 0.60* 0.68* 0.49 0.75*
Item 8—irritation 0.44 0.63* 0.70* 0.49 0.73*
Item 9—sensitivity 0.44 0.61* 0.68* 0.48 0.70*
Item 10—lesions 0.45 0.62* 0.65* 0.49 0.72*
Item 11—thickening 0.44 0.61* 0.64* 0.49 0.71*
Item 12—fatigue 0.38 0.61* 0.54* 0.44 0.60*
Item 13—embarrassment 0.38 0.69* 0.56* 0.46 0.61*
Item 14—choice of clothing 0.38 0.68* 0.50 0.46 0.59*
Data were pooled from BE VIVID and BE READY
DLQI Dermatology Life Quality Index, IGA Investigator’s Global Assessment, PASI Psoriasis Area and Severity Index,
PGAP Patient Global Assessment of Psoriasis, P-SIM Psoriasis Symptoms and Impacts Measure
*Correlation coefficients that are strong ([ 0.50)
a Changes from baseline to week 12 were used for PGAP as a result of substantial amounts of missing data at week 16
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above the acceptability threshold of 0.70; this
demonstrates that the P-SIM is consistent in its
measurement of signs, symptoms and impacts
of plaque psoriasis in patients whose disease
state has not changed, and that results are
repeatable.
The P-SIM demonstrated strong inter-item
correlations at both baseline and week 16, apart
from item 14 (choice of clothing), which had a
moderate correlation with items 3 (skin pain)
and 4 (burning) at baseline. P-SIM item scores
also showed moderate to strong correlations
with PASI, IGA, DLQI, DLQI item 1 and PGAP
scores at week 16, and with DLQI, DLQI item 1
and PGAP scores at baseline. The lower corre-
lations seen with PASI and IGA scores at base-
line may have been due to low variability in
these measures upon trial entry, owing to the
eligibility criteria for BE VIVID and BE READY
(PASI C 12 and IGA C 3). Together, these
results demonstrated good convergent validity
of P-SIM items.
The P-SIM item scores also demonstrated the
ability to discriminate between patient known
groups defined on the basis of absolute PASI
thresholds and IGA scores; statistically signifi-
cant between-subgroup score differences were
seen across all P-SIM items for nearly all known-
group comparisons.
Changes from baseline to week 16 in P-SIM
items were strongly correlated with those in
other patient-reported outcomes and moder-
ately correlated with those in clinician-reported
outcomes. Previously it has been reported that
patient-reported outcomes do not always cor-
relate well with clinician-reported outcomes,
highlighting the importance of including
patient-reported outcomes in clinical studies to
capture patient experiences [27, 28]. Changes
from baseline in items 12 (fatigue), 13 (embar-
rassment) and 14 (choice of clothing) all gen-
erally had slightly weaker correlations with
other outcomes, hypothesised to be due to the
concepts measured being more distal and more
difficult to assess compared with the more
proximal skin symptoms assessed by
items 1–11, which are also directly evaluated by
clinician-reported outcomes and DLQI item 1.
These results indicate that the P-SIM items are
sensitive to changes in the concepts they are
intended to measure.
RD thresholds were estimated, as recom-
mended by the FDA guidance for industry
patient-reported outcome measures [16]. This
was of particular importance as responder pro-
portions in P-SIM items 1 (itching), 3 (skin pain)
and 5 (scaling) have been identified as key sec-
ondary endpoints in bimekizumab phase 3
studies. Anchor-based analyses were prioritised,
as recommended by the FDA [16]; the RD
thresholds obtained ranged from 2.72 to 4.39
(Supplementary Table 5) and supported the use
of a four-point RD threshold to represent
marked clinical improvement and to define
responders in patients with moderate to severe
plaque psoriasis in clinical trials. Though vari-
ations around this four-point RD threshold were
seen, these were of limited amplitude. This is in
line with FDA feedback and US prescribing
information for compounds approved in psori-
asis, which suggest that a four-point threshold
Table 4 Intraclass correlation coefficients for P-SIM item
scores
P-SIM item ICC (n = 1002)
Item 1—itching 0.94
Item 2—redness 0.93











Item 14—choice of clothing 0.98
ICC intraclass correlation coefficient, P-SIM Psoriasis
Symptoms and Impacts Measure
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Fig. 2 eCDF curves of observed changes from baseline to
week 16 in P-SIM item scores by DLQI item 1 change score
category. a P-SIM item 1 (itching).b P-SIM item 3 (skin pain).
c P-SIM item 5 (scaling). Data were pooled from BE VIVID
and BE READY. DLQI item 1 was prioritised for the RD
anchor-based analysis as it is patient-reported, measured on a
directly interpretable ordinal scale, and its change from baseline
to week 16 had the highest correlation with those in P-SIM
items. Negative changes from baseline in P-SIM item scores
indicate improvement. Dotted lines show median values.
eCDFs for itching, skin pain and scaling items are shown as
these items were used as efficacy endpoints in the BE VIVID
and BE READY trials; findings for other items were similar.
eCDF empirical cumulative distribution function, DLQI
Dermatology Life Quality Index, P-SIM Psoriasis Symptoms
and Impacts Measure, RD responder definition
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is a relevant RD for a single-item score assessed
on an 11-point numeric rating scale [29, 30].
These results support the use of the P-SIM to
define efficacy endpoints measuring patient
experiences of signs, symptoms and impacts of
psoriasis. The use of a four-point RD threshold
over an 11-point numeric rating scale through-
out all 14 items represents a simple and strin-
gent criterion for defining marked clinical
improvement; however, responder analyses
using this threshold to assess treatment effect
will be restricted to patients reporting a score
of[ 4 at baseline. Complementary analyses or
endpoints, such as attaining a P-SIM score of 0
or 1, could be considered, as has been done for
similar instruments in trials of other com-
pounds approved in plaque psoriasis [31, 32].
This would allow all symptomatic patients to be
taken into account.
Lower RD thresholds for items 1, 3 and 5
(itch, skin pain and scaling, respectively) were
determined previously in preliminary phase 2b
data analyses (1.98–2.86-point reduction), and
were considered to represent meaningful
improvement in bimekizumab in psoriasis
phase 3 study protocols. The more stringent
four-point RD thresholds identified here instead
indicate marked clinical improvement.
Limitations of this study include the pro-
portion of missing P-SIM data; 304/1002 of
patients were excluded from the RD analysis
because of missing data due to technical issues
at baseline, week 16 or both. Although 30.3% of
randomised patients were not included in the
P-SIM RD estimation, the sample size included
(698) is on par with or greater than sample sizes
of psychometric validation studies of other
instruments in psoriasis [8, 33, 34]. It is also
important to note that those patients who were
excluded from the RD analysis had similar
baseline characteristics to those who were
included (with the exception of region, where a
larger proportion excluded were from North
America [49.3% of those excluded versus 28.8%
of those included]; Supplementary Table 6).
Furthermore, while the daily nature of P-SIM
completion helps to capture how patients’
experiences may change from day to day, the
regularity of assessment may affect overall
completion rates; however, the simulation to
confirm the weekly scoring rule demonstrated
that the results do not vary substantially when
the number of days included in the weekly score
change, thus showing that the weekly scores are
robust with respect to variation between days.
Additionally, completion rates were high in this
study even when using the 4-day missing
weekly score rule.
Additionally, there were substantial amounts
of missing data for the PGAP at week 16, limit-
ing its use in analyses to a 12-week period
instead. However, the RD analysis utilised sev-
eral robust anchors (both patient- and clinician-
reported), each yielding relatively similar results
(predominantly between 3 and 5 points). CDF
curves for each anchor showed separation
between those who experienced an improve-
ment and those who experienced no change at
a four-point improvement in P-SIM item scores.
Thus, it is likely that conclusions would be
similar if there had not been missing data on
the PGAP at week 16.
A large proportion of the 1002 patients
enrolled in the phase 3 BE VIVID and BE READY
trials were male (71.8%) and white (82.1%). It
has been suggested that male patients generally
have greater severity of psoriasis [35], leading to
a greater proportion being included in the trials;
however, another study has indicated that
female patients experience greater impact on
their quality of life [36], and the vast majority of
clinical trials exclude pregnant women, mean-
ing that they do not appear in true proportion
[37]. Additionally, while the majority of
patients in the general moderate to severe pso-
riasis disease population are white, this study
Fig. 3 eCDF curves of observed changes from baseline to
week 16 in P-SIM item scores by PASI absolute score
category. a P-SIM item 1 (itching). b P-SIM item 3 (skin
pain). c P-SIM item 5 (scaling). Data were pooled from
BE VIVID and BE READY. Negative changes from
baseline in P-SIM item scores indicate improvement.
Dotted lines show median values. eCDFs for itching, skin
pain and scaling items are shown as these items were used
as efficacy endpoints in the BE VIVID and BE READY
trials; findings for other items were similar. eCDF
empirical cumulative distribution function, PASI Psoriasis
Area and Severity Index, P-SIM Psoriasis Symptoms and
Impacts Measure
b
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may not fully represent the experiences of
patients with skin of colour, who may have
increased impact of psoriasis on quality of life
[38, 39]; for example, post-inflammatory
hyperpigmentation has a greater impact on
patients with skin of colour [40].
CONCLUSIONS
Here, the P-SIM weekly item scores demon-
strated excellent test–retest reliability alongside
good convergent validity, known-groups valid-
ity, and sensitivity to change in the concepts
they are intended to measure. The weekly
scoring rule applied was shown to be appropri-
ate, and a four-point RD threshold was estab-
lished for P-SIM item scores. This RD could be
used to assess treatment effects on the signs,
symptoms and impacts of psoriasis. Alongside
previous studies confirming content validity of
the P-SIM, this supports use of the instrument as
an outcome measure in clinical trials in patients
with psoriasis.
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